Late-life depression (LLD) is a growing public and global health concern with diverse clinical manifestations and etiology. This literature review summarizes neuroimaging findings associated with depression in older adults
C l i n i c a l r e s e a r c h additional risks of suicide, dementia, and worsened medical comorbidity. [3] [4] [5] Insufficient implementation of recommended interventions and limited access to care 6 results in a greater burden for both patient and caregiver.
Medical and psychiatric comorbidity of LLD
Depression and associated medical and psychiatric comorbidities reciprocally aggravate each other, exacerbating the burden of disability. Frequent disabling symptoms include lack of energy (97.5%), somatic anxiety (91.7%), insomnia (86.5%), suicidality (64.6%), motor retardation (63%), and cognitive impairment (61%). 7, 8 Sleep disturbances independently predict poor response in LLD. 9, 10 Cognitive deficits associated with LLD may be a prodrome of dementia, with cognitive impairment often persisting after remission of affective symptoms. 8, 11, 12 These cognitive impairments include deficits of information processing speed and executive functioning. 12, 13 Suicide is more prevalent in older depressed individuals than in any other age group, and more so in those with cognitive impairment. 14, 15 Comorbid depression frequently complicates medical conditions prevalent in older adults, such as stroke, [16] [17] [18] hip surgery, 19, 20 diabetes, and obesity. 21 Depression also correlates with a fourfold higher rate of death following myocardial infarction.
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LLD: underdiagnosed and undertreated
Underdiagnosis worsens the burden of LLD. 4 The stigma of depression may reduce symptom reporting and discussions about emotional distress. [23] [24] [25] By default, primary care physicians (PCPs) are the first line of care. 4 PCPs often lack the training to identify the clinical heterogeneity of LLD. 26 As a result, older adults are less likely to be diagnosed, treated, or referred to mental health specialists than younger patients. Furthermore, the psychosocial realities of aging exacerbate depression. The coupling of caregiver strain with subsequent bereavement at the loss of a loved one may increase depression and mortality risk. [27] [28] [29] Social isolation and disability from medical illness are significant psychosocial risk factors. 30, 31 Although effective treatments exist, undertreatment compromises outcomes. Long therapeutic response times may lead to premature discontinuation of treatment. Finding an optimal therapeutic regimen may take months. Meanwhile, the risks of undertreatment persist: noncompliance, worsening comorbidities, and suicide. 32 
Depression hypotheses: an iterative history
The mechanistic hypotheses of depression are diverse and representative of a multifactorial etiology. The monoamine hypothesis 33 suggests that monoamine deficiencies are responsible for depression. Several circadian rhythm disruption hypotheses have arisen involving phase shift and REM sleep advancement, both of which are affected by monoaminergic antidepressants. 34 The discovery of elevated cortisol in depressed persons 35 led to the hypothesis that dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis may contribute to depression. The inflammation hypothesis 36, 37 provided a mechanistic intersection between the HPA axis and monoamines by suggesting that proinflammatory cytokines mediate depression. Cytokines both stimulate the HPA axis and modulate monoamine activity in the brain. [37] [38] [39] Depression in late life is likely a convergence of multiple etiologies. Indeed, the vascular hypothesis of LLD 40 accounts for the cumulative cardiovascular effects of inflammatory, immune, and sleep 41 dysregulation, along with the disconnection of monoaminergic circuits affected by cerebrovascular disease.
Vascular hypothesis of depression
Vascular insufficiency was first proposed as a mechanism of mood and executive dysfunction by Binswanger in 1894. 42 The modern vascular depression hypothesis bridges the heterogeneous symptomatology of LLD with the aging-related process of cerebrovascular disease and inflammatory/immune dysregulation. The currently accepted pathogenic hypothesis of atherosclerosis and subsequent cerebrovascular disease suggests an immune-mediated chronic inflammatory response to endothelial injury. 43 As such, vascular disease may predispose, precipitate, or perpetuate the symptoms specific to LLD, including cognitive deficits, psychomotor retardation, lack of insight, and disability disproportional to severity of depression. 40, 44 The imaging hallmark of vascular depression is white matter lesions (WMLs), seen on magnetic resonance imaging (MRI) as white matter hyperintensities (WMHs). 32, 40, 45 The clinical expression of vascular depression has been conceptualized as a "depression-executive dysfunction syndrome," which includes executive function deficits with planning, sequencing, organizing, and abstracting. 46 Cumulative damage by WMLs may disconnect frontostriatal and limbic circuits responsible for mood and executive functions. 44, 47 Current standard of care for LLD
First-line pharmacotherapy
Expert consensus guidelines point to selective serotonin reuptake inhibitors (SSRIs) as first-line therapy in older adults. 48 Other medications used as first-line pharmacotherapies include: serotonin-norepinephrine reuptake inhibitors (SNRIs), mirtazapine, and bupropion. 49 Prior to 2003, tricyclic antidepressants (TCAs) were the most well-researched antidepressants for older adults. Nortriptyline, a second-generation TCA, has been found to be particularly effective in achieving remission in bereavement-related major depression. 27 A 2006 Cochrane review of pharmacotherapy for unipolar LLD reported no differences in acute efficacy between these different classes of antidepressants.
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Efficacy of antidepressants
Despite high placebo response rates in many well-designed controlled trials, antidepressants have proven to be more effective than placebo in treating LLD. A meta-analysis of nontricyclic antidepressants in older adults showed increasing response with longer periods of exposure (response defined as ≥50% improvement from baseline on depression rating scales). Response rates for treatment of 6 to 8 weeks, relative to placebo, ranged from 35% to 45.6% (OR 1.22). Treatment for 10 to 12 weeks elicited response rates ranging from 45.7% to 68.9% (OR 1.73). 51 When remission is achieved after acute LLD, consensus recommends that therapy be continued for 6 to 12 months. 48 A study with paroxetine (an SSRI) found benefit of maintenance therapy of 2 years, including patients in their first lifetime episodes.
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Adverse effects of antidepressants
Successful pharmacotherapy demands an acceptable ratio of therapeutic efficacy and side effects, in order to achieve a net benefit and preserve compliance. Older adults are particularly susceptible to anticholinergic effects, orthostatic effects, drug-drug interactions, and drug-comorbidity interactions. Discontinuation rates were categorically higher for antidepressants compared with placebo, and may undercut the efficacy of antidepressant medications. 51 A meta-analysis of antidepressant efficacy in LLD found that discontinuation rates due to adverse effects of pharmacotherapy (such as fatigue, insomnia, gastrointestinal distress, headaches, genitourinary symptoms, and sweating) ranged from 8% to 27% (OR 1.84).
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Psychotherapy
Psychotherapy is effective and generally well-tolerated. 53 Expert consensus guidelines endorse psychotherapy along with antidepressant medication as the treatment of choice for LLD. 48, 54 Specifically, cognitive behavioral therapy, problem-solving therapy, interpersonal psychotherapy, and supportive psychotherapy are first-line psychosocial interventions. 48 With mild depression and dysthymia, psychotherapy may be firstline treatment without pharmacotherapy. 48, 53 With treatment-resistant depression, a systematic review demonstrated the utility of psychotherapy compared with pharmacologic monotherapy. While the evidence may be insufficient to recommend psychotherapy as monotherapy or as augmentation to pharmacotherapy, 55 it has been observed that the psychotherapy may reduce attrition and improve medication adherence, resulting in better clinical outcomes. 56 C l i n i c a l r e s e a r c h
Treatment-resistant LLD: pharmacological strategies
Up to one third of depressed older adults experience treatment-resistant late-life depression (TRLLD). There are two divergent options for escalating therapy in TRLLD. The first involves changing to a different class of medication. 58 The second involves augmentation pharmacotherapy, if the first-line agent has led to partial response. 59 Atypical antipsychotics (aripiprazole and olanzapine) are the only approved augmentation agents for TRLLD. Proposed involvement of D3 dopaminergic receptors in the depression-executive dysfunction syndrome makes agonism of that receptor a logical target.
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D3 agonists include aripiprazole and pramipexole. 61 Other commonly used augmentation agents include lithium, thyroid hormone, and methylphenidate. 58, 62, 63 
Treatment-resistant LLD: somatic interventions
Nonpharmacologic somatic interventions may also be used for TRLLD. Electroconvulsive therapy (ECT) is the most effective treatment for LLD, 53 successful in 60% to 80% of cases of treatment-resistant depression. ECT has an important role in depression with suicidality and psychosis. [64] [65] [66] Vagal nerve stimulation and transcranial magnetic stimulation are two other therapies for pharmacotherapy-resistant depression, FDA-approved in 2005 and 2008, respectively.
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Neuroimaging in depression: current recommendations
The current indicated role of neuroimaging in depression by the American Psychiatric Association is as part of the safety assessment for ECT. MRI or computed tomography should be used to rule out neuroanatomical conditions (eg, space-occupying lesions) that would contraindicate ECT. Moreover, neuroimaging may be used to identify conditions with depressive symptoms that may not respond to conventional depression therapy, such as neoplasms, hydrocephalus, or marked atrophy. 32, 49 Neuroimaging: potential clinical role in LLD
Support for the clinical potential of neuroimaging
The purpose of this review is to present findings from the recent literature that substantiate the potential clinical role of neuroimaging in LLD to inform therapeutic decision-making and assess therapeutic efficacy.
A growing body of literature has associated neuroimaging findings with depression subtypes and treatment response. Within the framework of the vascular hypothesis, imaging has provided insights into the etiologies, neuroanatomical distribution, and neuropharmacology of LLD. Yet, there is a paucity of controlled trials testing the efficacy of neuroimaging biomarkers in treatment selection and therapeutic assessment. There is as-yet unrealized potential for the translation of neuroimaging from the laboratory into the clinic. Controlled trials are needed to bring about the evidencebased recommendations required for clinical implementation.
Clinical neuroimaging for LLD: proposed therapeutic mechanisms
A potential clinical use of neuroimaging may be to identify the type(s) of therapy most likely to induce remission and shorten the time needed to arrive at optimal dosing. Specifically, the development of clinically validated imaging biomarkers might be used to identify older depressed adults most and least likely to respond to pharmacotherapy. These biomarkers may help determine the best initial dose of antidepressant pharmacotherapy. In order to guide early dosing adjustments, neuroimaging can potentially identify brain changes associated with effective dosing. This could reduce the lag between onset of treatment and clinical response. Overall, the goal is to develop neuroimaging biomarkers that inform the best initial therapy, decrease time between treatment onset and response, and increase remission rates for LLD.
Neuroimaging biomarkers of therapeutic response and disease progression
Studies using various MRI modalities have identified potential neuroimaging biomarkers associated with LLD, remission, and treatment response. These findings are reviewed below. servations of atrophy in the various regions associated with LLD. Significant atrophy was found within the orbitofrontal cortex (OFC), hippocampus, putamen, and thalamus. Atrophy of the caudate presented a trend toward significance. 67 In spite of variability within the literature, the most frequently observed regions of atrophy in LLD are the frontal lobe, limbic system, basal ganglia, and thalamus. 68, 69 Within the frontal lobe, atrophy has been observed in the OFC, 68, [70] [71] [72] [73] [74] and the anterior cingulate cortex (ACC). 74, 75 Volumetric decreases of the dorsolateral prefrontal cortex (dLPFC) and subregions of the dLPFC have been also been observed. 68, 76 An intricate frontal subregion analysis by Andreescu specifically associated volume loss in specific regions of the frontal lobe, including the dLPFC (frontal superior and superior middle areas), with duration of depression. 68 Within limbic structures, hippocampal atrophy has been most frequently observed. 68, 70, 73, 74, [77] [78] [79] [80] [81] Hippocampal subfields specifically affected include CA1-CA3, dentate gyrus, and subiculum. 74, 80, 81 Atrophy of the amygdala has also been observed. 68, 73, 74, 82 Basal ganglia atrophy has been described within the caudate, 69, 83 putamen, 68, 83 and pallidus.
Structural MRI: description
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Structural MRI associations with LLD: hyperintensities
WMLs are markers of cerebrovascular burden associated with aging, [84] [85] [86] hypertension, 85,87 cardiovascular dysautonomia, 88 ischemia, 85, 89 oligemia, 89 and diabetes. 86 WMLs are identified on T2-weighted MRI as WMHs and are a hallmark of vascular depression. 40 LLD is asso- Non-remitted LLD was associated with smaller volume in the left hippocampus, compared with both controls and subjects with remitted LLD. Although changes could not be pinpointed to specific hippocampal subfields, nonremitted LLD was roughly associated with contraction in CA1, and CA2, while both remitted and non-remitted LLD was roughly associated with contraction of the dentate gyrus and expansion of the subiculum and CA2-3, compared with controls.
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ciated with greater hyperintensity volume [90] [91] [92] [93] (Table II) . A meta-analysis observed that older adults with depression (onset at any age) had 2.15 and 1.92 greater odds of periventricular WMH (PVWMH) and deep WMH (DWMH), respectively, when compared with healthy age-matched controls. The odds were steeper in adults with late-onset depression, whose odds of PVWMH and DWMH were 2.57 and 4.51 times greater, respectively. 93 Similarly, PVWMH and DWMH have also been associated with cognitive decline in older adults. [94] [95] [96] More recent studies of LLD have found WMH in specific tracts connecting the frontal lobe with limbic structures and the basal ganglia, including the cingulum bundle, uncinate fasciculus, and superior longitudinal fasciculus. [97] [98] [99] Structural MRI associations with LLD: white matter integrity DTI quantifies myelin tract integrity as functional FA. Decreased FA implies loss of myelin integrity, which may be mediated by inflammatory, immune, or cerebrovascular processes. 100 FA deficits in LLD have been found in fronto-subcortical and fronto-limbic tracts, including the uncinate fasciculus, [101] [102] [103] [104] anterior thalamic radiation, superior longitudinal fasciculus, [102] [103] [104] and PCC 105 (Table III) .These deficits are congruent with pathways implicated in the depression-executive dysfunction syndrome of LLD. 45, 46 Structural MRI association with LLD treatment outcomes: regional atrophy
In addition to investigating potential neuroimaging biomarkers specific to LLD, studies have sought structural MRI predictors of antidepressant treatment response. Smaller hippocampal volumes have been associated with poor therapeutic outcomes in LLD (Table  IV) . Indeed, smaller hippocampal volumes at baseline predicted treatment resistance among 60 depressed older adults after 12 weeks of protocolized pharmacotherapy. 106 Similarly, of 92 depressed older adults receiving 2 years of protocolized pharmacotherapy, nonremitters were found to have smaller hippocampi at 2 years than at baseline. 107 In that same study, a positive correlation was observed between the rate of hippocampal atrophy and Montgomery-Åsberg Depression Rating Scale (MADRS) scores. 107 Additionally, lower baseline gray matter volume in the dorsal and rostral ACC were associated with nonremission after 12 weeks of escitalopram in a cohort of 41 depressed older adults. 108 Early-onset depression was associated with lower FA in the left uncinate fasciculus, compared with both controls and patients with mid-to-late-onset LLD. 119 potentially explaining the discrepancy.
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Functional MRI: description
Functional MRI is capable of identifying pharmacologic challenges in real time. 120 As such, fMRI has the potential to prognosticate early interventional efficacy (as early as minutes after initiation of pharmacotherapy). Functional MRI can be subdivided into task-based and resting-state modalities. Task fMRI uses blood-oxygen level dependent (BOLD) signal to identify areas of increased synaptic activity. Regions with increased BOLD signal during a predefined task are considered to have functional associations with the performance of the task. Task fMRI can also identify areas of functional connectivity (FC). Distinct regions of the brain are said to be functionally connected if their activations display temporal synchronicity. Resting fMRI, in turn, assesses the activity and FC of resting state networks, such as the default mode network (DMN). Resting state networks are suspended during goal-directed behavior.
Functional MRI associations with LLD: resting-state fMRI
Resting-state fMRI has highlighted changes within the DMN and cognitive control network (CCN) in LLD 121 (Table VII) . Relative to healthy controls, adults with LLD were observed to have low resting FC within the CCN and high resting FC within the DMN. 122 Regions within the CCN noted for decreased FC were the dorsal ACC (dACC) with the dLPFC. Regions within the DMN with increased FC were the precuneus, subgenual ACC, and ventromedial prefrontal cortex (vmPFC). 122 Alexopoulos et al found FC alterations in the CCN and DMN are congruent with LLD symptomatology. The CCN is thought to mediate goal-directed behavior and inhibition of negative biases, both of which are deficient in LLD. 122 The DMN is thought to mediate self-referential thinking, which is susceptible to negativity bias in LLD. (Table VIII) . These findings are congruent with the observation by Alexopoulos et al of diminished resting-state FC within the CCN in LLD. 122 Using an emotional oddball task meant to investigate the relationship between emotional and attentional processing, 125 Wang et al observed task-based differences in DMN activity between acutely depressed, remitted, and healthy older adults. Acute and remitted LLD was associated with lower activation of the ACC, anterior portion of the posterior cingulate cortex (PCC), and inferior parietal areas, compared with controls. 126 Acute LLD had increased deactivation of the posterior PCC and decreased activation of the middle frontal gyrus, when compared with both remitters and healthy controls. 126 Task-based MRI has been further used to substantiate a link between cerebrovascular pathology and functional brain activity in LLD. Specifically, WMH burden was correlated with limbic hyperactivation in an affective reactivity task.
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Functional MRI associations with LLD treatmentoutcomes: task-based fMRI
Research into the use of resting-state and task-based fMRI to predict and assess therapeutic efficacy in LLD is sparse relative to research of fMRI in mid-life depression (Table IX ). Aizenstein et al described the potential utility of task-based fMRI of the prefrontal cortex (PFC) to prognosticate treatment response in LLD. 124 Prior to treatment with an SSRI, 13 participants with LLD had diminished task-based ("preparing to overcome" prepotency task) activity in the dLPFC relative to controls. After a 12-week trial of an SSRI, all 13 participants with LLD experienced symptomatic improvement in aggregate. Moreover, post-treatment task-based activity in the dLPFC increased (ie "normalized") toward Subjects with acute LLD and remitted LLD demonstrated decreased activation in the anterior PCC and inferior parietal areas, compared with controls. Acutely depressed subjects demonstrated decreased activity in the right middle frontal gyrus and the posterior PCC, compared with both controls and patients with remitted LLD.
C l i n i c a l r e s e a r c h dLPFC activity levels of healthy controls. 124 Brassen et al also observed the potential prognosticating power of task-based fMRI of the PFC with a similar preand postpharmacotherapy study. 128 When participants with LLD were asked to evaluate emotional words at baseline, negative words resulted in hypoactivity of the vmPFC relative to positive words. At 7-month followup, at which point the majority of subjects experienced symptomatic improvement, the difference in task-based activation between negative and positive words had significantly diminished in magnitude. 128 The importance of the PFC was further demonstrated by Wang et al by looking at acute LLD, remitted LLD, and controls using an emotional oddball task. Diminished activation of the middle frontal gyrus was specific to acute LLD, when compared with subjects with remitted LLD and controls. 126 Taken together, task-based fMRI studies suggest that LLD is associated with hypoactivity in the PFC, which can diminish the inhibitory influence over associated limbic structures. 128, 129 Furthermore, "normalization" of PFC hypoactivity (ie, increased activity) is associated with treatment response.
Functional MRI associations with LLD treatment outcomes: resting-state fMRI
A resting-state fMRI study by Alexopoulos et al observed that low FC in the CCN at baseline predicted treatment resistance 122 (Table X) . A second study by Andreescu et al described how FC within the DMN might predict treatment response in LLD. Specifically, prior to 12 weeks of antidepressant pharmacotherapy, eventual nonresponders had increased FC between the PCC and dACC and cuneus, and decreased FC between the PCC and medial PFC and precuneus, when compared with eventual treatment responders. 130 Moreover, increased FC in the left striatum over the course of antidepressant therapy was associated with treatment resistance.
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Mechanisms of psychopathology observed with MRI
Depression in late life is the cumulative expression of multiple etiologies associated with aging. 131 For example, the inflammation and immune hypotheses coexist within a vascular depression framework. Aging induces immune dysregulation, 132 which in turn results in a proinflammatory state. Immune dysregulation and chronic inflammation can directly mediate depressive symptoms, cognitive deficits, 133, 134 and cerebrovascular disease. 43 Structural and functional associations with LLD presented in this review support the idea of a depression-executive dysfunction syndrome as a clinical manifestation of vascular depression.
This review of neuroimaging in LLD links hyperintensity burden to structural and functional MRI findings in older adults with depression. LLD is associated with cerebral atrophy, loss of myelin integrity, and cerebrovascular changes observed as WMH burden, which is a hallmark of vascular depression. 40, 100 WMHs were found along tracts connecting frontal and limbic structures, [97] [98] [99] which in turn were found to have diminished myelin integrity. 67, 101, 102 Areas of gray matter connected by these white matter tracts, specifically frontostriatal and limbic areas, were found to have significant atrophy. [67] [68] [69] Resting-state fMRI further outlined the effects of WMH with the observation of diminished FC within frontostriatal-limbic areas that make part of the CCN.
122 Task-based fMRI was able to correlate limbic hyperactivation with WMH burden during an affective reactivity task.
Mechanisms of treatment resistance and response observed with MRI
Pretreatment structural and functional correlates of treatment resistance (atrophy, WMH, FC) appear to associate the heaviest initial burden of pathology with the smallest likelihood for remission. Smaller hippocampal volumes and greater WMH burdens at baseline were associated with eventual treatment resistance, while increased rate of hippocampal atrophy was associated with worsening symptoms of LLD. 106, 107 Whole brain WMHs, PVWMHs, and DWMHs at baseline were associated with treatment resistance. Resting-state fMRI studies found that low FC in the CCN and high FC in the DMN predicted treatment resistance. 122, 130 Task-based fMRI has the potential to be useful in the longitudinal assessment of therapeutic efficacy. Those treated effectively for LLD may have task-based fMRI activity that approaches the activity patterns of healthy controls over time. One could consider this an effective "normalization" of brain activity, or a reversal of depression pathology. An example of this was the association of treatment response with the "normalization" of dLPFC activity in response to an overcoming-prepotency task. That is, at baseline, those with LLD had low task-based activity in the dLPFC relative to healthy controls. Increases in dLPFC activity during the course of therapy was associated with symptomatic improvement.
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Sources of variability among studies
MRI studies of LLD are burdened by significant variability. Research methods are one culprit. Among the most variable aspects of experimental design are the following: age cutoffs used to define late-life, subjective symptom inventories, remission criteria, types of antidepressants administered, and tasks used in task-based fMRI.
Cerebrovascular burden: a treatment-resistant etiology of LLD
The most variable factor in the study of LLD is LLD itself. This disease is heterogeneous in its presentation, clinical response, and etiology. The presentation of LLD represents the cumulative burden of various risk- C l i n i c a l r e s e a r c h factors crossing a pathologic threshold. 44 Nevertheless, the neuroimaging determinants of treatment-resistant LLD were predominantly associated with frontostriatal and limbic areas. Cerebrovascular findings in these specific areas are the hallmark of vascular depression, and help explain the common presentation of older adults with executive dysfunction-depression syndrome. The neuroimaging determinants of treatment resistance may be more than prognostic biomarkers. They may also identify those individuals whose LLD is heavily mediated by cerebrovascular burden. In contrast, those more likely to remit may possess a LLD less reliant on cerebrovascular burden and more heavily mediated by reversible pathogenic processes. The cumulative irreversible burden of cerebrovascular insults may be responsible for treatment resistance for many with LLD.
Potential clinical applications of MRI for LLD
The translation of neuroimaging for clinical use in LLD requires further research. Potential applications of such translational research include the following:
• Identification of the best initial treatment modality:
LLD is mediated by the cumulative effect of various pathogenic processes. A potential clinical application of neuroimaging can be to identify structural or functional biomarkers associated with likelihood of response to different types of pharmacotherapy. This may expedite the identification of optimal patientspecific treatment modalities. • Optimization of initial antidepressant dose: functional MRI can identify changes within the brain within seconds. 120 Dose-dependent amygdala activation responses to IV citalopram have been observed within seconds. 120 It may be possible to use fMRI to identify neuroimaging biomarkers associated with an optimal therapeutic state within the first few hours or minutes after initiating antidepressant therapy.
• Earlier measures of therapeutic efficacy: further clinical research may help translate structural and functional MRI for clinical practice, in order to create individualized "brain maps" for each patient with LLD. Follow-up scans after commencement of therapy (eg, SSRI) can be used to look for "normalization" of the most pathogenic features of a patient's "brain map." These iterative scans could then justify early alterations in the course of treatment, and expedite the arrival at optimal therapy.
Novel targets based on vascular depression and executive dysfunction-depression syndrome
The frontostriatal-limbic distribution seen in vascular LLD lends itself to therapeutic agents targeted at unconventional receptors. Specifically, dopamine D3 receptors, kappa-opiate receptors, and mu-opiate receptors may be promising targets.
Aripiprazole: partial D3 receptor agonist
The involvement of the frontostriatal-limbic pathways in vascular LLD has been well documented, as have been the associated symptoms of depression and executive dysfunction. 46 The atypical antipsychotic, aripiprazole, is currently not a first-line intervention for LLD. Neuroimaging results, however, support the potential therapeutic utility of expanding the role of a D3 partial agonist, like aripiprazole. Those with predominantly vascular depression may have the most to gain, since MRI studies have shown atrophy, diminished functional connectivity, heavy WMH burden, and task-based fMRI hypoactivity within frontostriatal and limbic areas in LLD. These regions appear to be crucial for vascular depression, 40, 46 and are replete with D3 receptors. 135 Those with executive dysfunction-depression syndrome in late life are more often resistant to first-line therapies, and may benefit from interventions targeting D3 receptors. Animal studies have shown that D3 receptor agonists reduce depressive symptoms. [136] [137] [138] Moreover, an open-label pilot study found aripiprazole effective at treating TRLLD. Further evaluation with a randomized control trial has recently been completed by the authors, suggesting the efficacy and safety of aripiprazole in older adults, whose episodes of major depression did not respond fully to venlafaxine.
Buprenorphine: kappa-opiate receptor antagonist and mu-opiate receptor partial agonist
Neuroimaging findings in LLD also support the potential use of buprenorphine for those with vascular depression and TRLLD. Buprenorphine is a kappa-opioid receptor antagonist and mu-opioid receptor partial agonist. Frontostriatal and limbic findings in LLD support mu and kappa receptors as therapeutic targets, as kappa receptors have been found throughout frontostriatal and limbic structures. 139, 140 Mu receptors are also plentiful in limbic regions of the rhesus monkey, including the globus pallidus, cingulate cortex, insula, caudate, and putamen. 141 Agonism of kappa receptors have been found to induce depressive symptoms in rats, while antagonism reduces depressive symptoms in forced swim tasks. 142 Although venlafaxine induces antidepressant effects in mice, this effect is diminished in mu-receptor knockout mice. 143 Furthermore, paroxetine, an SSRI, increases mu-receptor density in mice, suggesting a connection between mu-opiate receptors and the antidepressant effects of SSRIs. 144 The therapeutic potential of buprenorphine in LLD is further supported by the observed decrease in mu-receptor density with age. 145, 146 A recent open-label trial in older adults found buprenorphine to be safe and effective in the treatment of LLD. 147 Further evaluation with randomized control trials are warranted to generate the evidence base required for clinical application of this novel approach.
Proposed steps for translation of neuroimaging into clinical practice
Other neuroimaging modalities: magnetic resonance spectroscopy and positron-emission tomography This review only summarizes structural and functional MRI findings in LLD. Nevertheless, other imaging modalities have been applied in the research of LLD: positron emission tomography (PET) and magnetic resonance spectroscopy (MRS). PET is used to make dynamic measurements of neurotransmitter receptor occupancy and other potential molecular mediators of LLD. In-vivo MRS can measure the relative quantities of molecules in specific regions of the brain, including membrane-bound molecules, intracellular molecules, lipids, enzymes, amino acids, and neurotransmitters. These imaging modalities can serve to further refine our understanding of the etiological mechanisms of LLD.
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Improved technology
Technological innovation is accelerating. Most studies of depression have used magnets that are 3 Tesla or smaller. As more powerful magnets become the new standard, spatial resolution, temporal resolution, and image contrast will improve. Innovations in image processing algorithms will further improve signal-to-noise ratios. The advancement of technology will reduce data variability, and allow for more precise observations of disease processes.
Neuroimaging as a clinical tool for optimizing any clinical intervention
The studies in this review overwhelmingly use SSRIs or SNRIs (at predominantly serotonergic doses) for treatment of LLD. As such, the neuroimaging findings in this review primarily support the use of MRI as a clinical tool for optimizing serotonergic pharmacotherapy. MRI can potentially identify the best initial dose of an SSRI or SNRI. Follow-up scans could then inform whether a starting dose is sufficient, or whether changes in a person's brain are associated with a trajectory toward treatment response. Nevertheless, this paradigm may be applied to other therapeutic modalities. Proper research can identify neuroimaging biomarkers associated with the likelihood of treatment response for other medications such as aripiprazole or buprenorphine. In order to translate neuroimaging into clinical practice, randomized controlled trials are needed to test how well neuroimaging biomarkers can inform treatment selection and modification. o 
